Abstract
The activities of three new quinolone compounds against vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) and their synergism with several commercially available antibiotics were investigated. Of the three novel new quinolone compounds tested, compound (1) was the most active against VRE and MRSA. Partial synergism was documented between compound (1) and the commercially available antibiotics such as ampicilin (ABPC), gentamicin (GM), minomycin (MINO), fosfomycin (FOM) and vancomycin hydrochloride (VCM) except in the case of ABPC and VCM against MRSA. Timekill analysis for compound (1) and the commercially available antibiotics such as ABPC, GM, MINO, FOM and VCM was performed by using one strain of VRE and one of MRSA. With the increase of the concentration of the added compound (1), the survival bacterial numbers decreased gradually. The above mentioned results suggested that compound (1) could reduce the daily administration dose of the commercially available antibiotics for the cure of nosocomial infection with its partial synergistic effect, and would have the possibility of reducing the occurrence of the nosocomial infections caused by VRE and/or MRSA.
